Trxc — Stock Buy Or Sell

: Shareholders at the time of the merger were entitled to receive the $0.35 per share cash payout.

: The symbol transitioned from TRXC to ASXC as part of this corporate shift.

The ticker is no longer active for trading. TransEnterix, the company originally associated with that symbol, rebranded as Asensus Surgical and changed its ticker to ASXC in March 2021. Subsequently, Asensus Surgical was acquired by KARL STORZ and its stock was officially delisted in August 2024. Stock Status and Delisting trxc stock buy or sell

: KARL STORZ acquired the company primarily for its Senhance Surgical System and the development of the next-generation LUNA™ System , aiming to integrate these into their global endoscopy portfolio.

: Leading up to its acquisition, the company reported a Q2 2024 revenue of $2.2 million but sustained a net loss of $25.7 million for the same period. Investment Outlook : Shareholders at the time of the merger

: Under the terms of the merger agreement, all outstanding shares of ASXC were acquired for $0.35 per share in cash .

Since the company is now , it is not possible to buy or sell shares on public markets. : Leading up to its acquisition, the company

: On August 22, 2024, KARL STORZ finalized its acquisition of Asensus Surgical.